Lachlan Hay interview for Pinksheet gives insights as to pricing, distribution, avails and travails, beerakrautcy, and informative on problems

132 views
Skip to first unread message

Uhohinc

unread,
Jun 24, 2017, 4:57:31 AM6/24/17
to Clinuvel Afamelanotide Scenesse Vitiligo Porphyria CUV ASX.CUV CLVLY ur9

(Next post as it did not copy)

Lachlan Hay Hor-Hay. (Maybe "hey" is an American only idiom not used by Australian English speakers.)

There must be an underlying motivation for this story. I'll pick apart at it. It's an absolutely ungoogleable search to locate.

Juan Cierva

unread,
Jun 26, 2017, 2:10:40 PM6/26/17
to Clinuvel Afamelanotide Scenesse Vitiligo Porphyria CUV ASX.CUV CLVLY ur9
Is this the article you are referring to?

I entered my information for a free trial to obtain access but have not heard anything back yet.

https://pink.pharmamedtechbi.com/PS120803/Interview-Clinuvel-A-Company-That-Does-The-Unusual

meincuv

unread,
Jun 27, 2017, 4:54:29 AM6/27/17
to Clinuvel Afamelanotide Scenesse Vitiligo Porphyria CUV ASX.CUV CLVLY ur9
Interview__Clinuvel.pdf

Juan Cierva

unread,
Jun 27, 2017, 10:07:26 AM6/27/17
to Clinuvel Afamelanotide Scenesse Vitiligo Porphyria CUV ASX.CUV CLVLY ur9
Thanks for posting.

It's disappointing to hear that the FDA NDA filing won't happen in 1H 17. Now, they're saying hopefully by year-end.

I didn't realize that the individual country reviews would be as onerous, as well. I knew price had to be agreed upon, but it looks like there's much more involved, including the costs and resources involved with setting up the distribution centers.

I'm somehow still optimistic, but this stock sure requires a hell of a lot of patience. We've been in this stock for nearly 12 years now and we have just barely doubled our money. I am not sure if our patience will last more than a couple of years without some major advances.

Farma Zutical

unread,
Jul 2, 2017, 8:11:11 AM7/2/17
to Clinuvel Afamelanotide Scenesse Vitiligo Porphyria CUV ASX.CUV CLVLY ur9
Quote from the interview:

"It’s not so much that we won’t budge on price, we’ve set a very transparent price for all countries, treating all expert centres equitably. All of these [health technology assessment/pricing/reimbursement] agencies say to me, I want transparency, I want to know what everyone else is paying, and I said, OK that’s the price and we can structure that way. We’ve said from day one… that there will be no arbitrage across countries.
It’s bizarre to them. They’ve not seen this before. I think there’s a certain element of disbelief. [They think:] “Okay, what you’re saying publicly is this but really we think you’re doing this.”

Lachlan says "I" and "me." Not us. It sounds as if he is the acting CEO and the PW is somewhat sidelined. Perhaps PW's health issues forced him to step aside and now he's only handling minor tasks.

Uhohinc

unread,
Jul 2, 2017, 2:42:49 PM7/2/17
to Clinuvel Afamelanotide Scenesse Vitiligo Porphyria CUV ASX.CUV CLVLY ur9
With in mind Dr Wolgen in youth being of higher caliber football player. I think to get to his level of play is being born ten percent with muscles and physical coordination and ninety percent in the mind habits with motivation, focus, showing up even when you have other things to do, practice and preparation, confidence, leadership etccc....Dr Wolgen is a very accomplished and makes tremendous demands on himself type personality whom pushes himself..........and these personalities type also push and demand and expect those around him to subscribe to their culture and circles. But unlike football, the drug and regulatory process does not have lines, ignores goal posts and scoring is not reliable, the rules are not followed and ambiguity, and the refferees are not experts and fickle minded.

If Lachlan is still there now after all these years under Dr Wolgen or may appear to morphed as equal mostly, I think Lachlan is up to Dr Wolgen standards of play and probably transformed somewhat into Dr Wolgen style and characteristics. In some ways, for Lachlan to have survived the Dr Wolgen managing style, he may be even more suitable a personality to deal with difficulties in people in the organization and outside the organization a more diplomatic manner.

Dr Wolgen could control most all in the Clinuvel organization and team strategy and call the plays, but he could not fire a inept EMA bureaucrat or the German referenced regulators and or collusion of insurance companies whom tried to end Clinuvel.

Uhohinc

unread,
Oct 15, 2021, 11:09:05 PM10/15/21
to Clinuvel Afamelanotide SCENESSE senescence CUV ASX.CUV CLVLY ur9
https://youtu.be/dZqcb0jR3Eo This video is excellingly informative to its intended audience of XP patients, family, and of interested.  Yet as an investor, I think it finally brings out the private unknown Lachlan Hay that even in the just above post I did guessing about him and somewhat about him in 2017.  This video impressed me with its content, presentation, but impressed me in that L Hay is..........very articulate................very competent.............very well knows his subject and informed of any and all Clinuvel............with a balance of humbleness right in the beginning,,,, I had never thought Dr. Wolgen could be replaced, but L Hay changed the mis perception of him here I had.
Reply all
Reply to author
Forward
0 new messages